1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
626F6F72FB7EA8B1785257768003B2049
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/pharmaceutical-bioequivalence-studies-key-cost-quality-productivity-metrics
18
19
203.95.131.208
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services

Pharma Bioequivalence Strategies: Performance Metrics, Processes & Trends

ID: POP-234


Features:

26 Data Graphics

161 Metrics

4 Best Practices


Pages: 49


Published: Pre-2014


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Generic pharmaceutical manufacturing companies are expected to increase outsourcing for bioequivalence studies to less regulated countries in the near future. However, selecting a contact research organization (CRO) that is cost efficient and at the same time provides quality results is often challenging. In addition, companies have to make sure that CROs are adhering to protocols and correct guidelines when conducting bioequivalence studies.


Best Practices, LLC conducted this timely benchmarking research that identifies key cost, quality and productivity metrics for the process of conducting bioequivalence studies required to bring a new generic drug to market. Specifically, this study looks at the growing trend in outsourcing for bioequivalence studies. In addition, the study also includes executive insights, lessons learned and best practices for productivity in the bioequivalence study process. Generic companies can use the comparative metrics in this study to evaluate their current bioequivalence testing programs.


Industries Profiled:
Pharmaceutical; Service; Research; Health Care; Manufacturing; Biotech


Companies Profiled:
Apotex; Clinigene; Dr Reddy's Laboratories; GeneraMedix; Merck; Lupin; Perrigo Company; Naari; Ranbaxy; ratiopharm; Sanofi-aventis; Roxane Laboratories; Teva Pharmaceutical Industries Ltd; Sun Pharmaceutical; Wockhardt; ZARS Pharma; Zentiva; Zydus Cadila

Study Snapshot

Twenty executives at 18 leading generic pharmaceutical manufacturing companies participated in this benchmarking study. Most benchmark participants hold job titles at the director-level and above, and nearly half work in R&D organizations. The greatest number—42%—are located in the US, with another 37% in India. Qualitative and quantitative data for this study were collected through an online survey instrument.

Sample Key Findings

Use of Less Regulated Regions: A majority of participating companies (56%) outsource fewer than one-quarter of their bioequivalence studies to CROs in less-regulated regions, such as India, China, Russia and Eastern Europe.

  • Current Outsourcing Locations: India gets the lion’s share of the Bioequivalence (BE) outsourcing that’s goes to less-regulated regions, with 78% of the Generic companies using CROs there.
  • Future Outsourcing: Generic companies in the study expect to increase BE outsourcing levels to countries in less-regulated regions in the next 24 months, especially in India, where 65% expect increases.
  • Volume of Outsourcing: Up to 80% of the benchmarked Generic companies routinely outsource key bioequivalence testing functions. All use outsourcing to some extent.
Table of Contents

Executive Summary
    • Research Overview
    • Benchmark Participants
    • Key Findings & Observations
  • Outsourcing & Geographic Trends
  • Volume & Cost Metrics
  • Bioequivalence Practices & Processes
  • Clinical Quality Assurance Strategy, Structure & Performance
  • Best Practices & Lessons Learned